Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-613 vs colchicine for prevention of acute gout flares during initiation of urate-lowering therapy
CTR20240434Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-613 in gout, sponsored by 3S Guojian Pharmaceutical. Started Feb 2024; status: completed.
02
Drugs
SSGJ-613
03
Conditions
gout
Beyond the preview
Go deeper on CTR20240434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240434.